Real World Data Trials

Guiding you to the future of clinical development.

Real-world data studies are unquestionably the trials of the future – the near future. As this dynamic field evolves, we use experience-based approaches to guide you through efficiency, productivity, and sustainability when it comes to using real world data. So when you’re ready to incorporate real world data for research or for regulatory decisions, we’re ready to lead.

Today, legislators and policy makers are actively engaging in dialogue on the value of real-world data. In fact, the FDA is developing specific guidelines on the use of real-world evidence (RWE) to support regulatory decision-making – a critical step forward to understanding real-world patient care and outcomes in the drug-approval process. The EMA has begun similar initiatives, and in the Asia-Pacific region, interest in leveraging real world data in clinical research is dramatically on the rise.

According to a recent report by the Economist Intelligence Unit (EIU), titled The Innovation Imperative: The Future of Drug Development, the use of RWD has increased steadily since 2008, mostly in post-marketing trials. Most notably, drugs developed using RWD have a 21% higher likelihood of launch across all therapeutic areas. 

Bar graph illustrating the increase in likelihood of launch for real world data clinical trials.

We are always available for a conversation.